Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction-Reference-Cited by-同舟云学术

Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction

Published:2015-03-18 Issue:5 Volume:107 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Heemskerk-Gerritsen B. A. M.,Seynaeve C.,van Asperen C. J.,Ausems M. G. E. M.,Collée J. M.,van Doorn H. C.,Gomez Garcia E. B.,Kets C. M.,van Leeuwen F. E.,Meijers-Heijboer H. E. J.,Mourits M. J. E.,van Os T. A. M.,Vasen H. F. A.,Verhoef S.,Rookus M. A.,Hooning M. J.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/107/5/djv033/17314430/djv033.pdf

Reference31 articles.

1. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium;Ford;Am J Human Gen,1998

2. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews;Struewing;New Engl J Med,1997

3. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study;Bergfeldt;Lancet,2002

4. Grp NYBCS. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2;King;Science,2003

5. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers;Metcalfe;J Clin Oncol,2004

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?;npj Breast Cancer;2024-09-05

2. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

3. Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers;Gynecologic Oncology;2024-08

4. Identification of key molecular pathways and genes in BRCA1 and BRCA2-mutant ovarian cancer: evidence from bioinformatics analysis;Genome Instability & Disease;2024-07-12

5. Decision aids for female BRCA mutation carriers: a scoping review;BMJ Open;2024-06